European regulators cast doubt on Biogen Alzheimer’s treatment
EMA vote deals a setback to controversial $56,000-a-year treatment
Alzheimer’s drug hopes see Biogen shares surge 27%
Pharma group resurrects pipeline therapy it abandoned as ineffective earlier this year
Drug that can halt Alzheimer’s may be on the horizon
Early-stage clinical trial involving aducanumab has yielded promising results
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
The GlossOpens in new window
Read the digital edition of The Gloss magazine now
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices